[Bloomberg] Boehringer’s New Lung Drug to Cost $96,000 a Year

Boehringer Ingelheim GmbH priced its new treatment for a deadly lung-scarring disease at $96,000 a year, just higher than Roche Holding AG’s (ROG) competing product. Read More